These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 21191718

  • 21. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 22. [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD].
    Schaal KB, Engler C, Schütt F, Scheuerle A, Dithmar S.
    Ophthalmologe; 2008 Jun; 105(6):538-43. PubMed ID: 18299845
    [Abstract] [Full Text] [Related]

  • 23. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Jun; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 24. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN.
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [Abstract] [Full Text] [Related]

  • 25. Fundus autofluorescence not predictive of treatment response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Chhablani J, Kozak IR, Mojana F, Cheng L, Morrison VL, Wang H, Kim JS, Dustin L, Azen S, Freeman WR.
    Retina; 2012 Sep; 32(8):1465-70. PubMed ID: 22466489
    [Abstract] [Full Text] [Related]

  • 26. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
    Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N.
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
    [Abstract] [Full Text] [Related]

  • 27. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA.
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [Abstract] [Full Text] [Related]

  • 28. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.
    Lazic R, Gabric N.
    Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):68-73. PubMed ID: 17111146
    [Abstract] [Full Text] [Related]

  • 29. Intravitreal bevacizumab for peripapillary choroidal neovascular membranes.
    Davis AS, Folk JC, Russell SR, Sohn EH, Boldt HC, Stone EM, Mahajan VB.
    Arch Ophthalmol; 2012 Aug; 130(8):1073-5. PubMed ID: 22893085
    [No Abstract] [Full Text] [Related]

  • 30. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 31. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
    Carneiro AM, Falcão MS, Brandão EM, Falcão-Reis FM.
    Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
    [Abstract] [Full Text] [Related]

  • 32. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 33. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 34. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
    Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S.
    Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
    [Abstract] [Full Text] [Related]

  • 36. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 37. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.
    Retina; 2006 Jun; 26(5):495-511. PubMed ID: 16770255
    [Abstract] [Full Text] [Related]

  • 38. The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation.
    Ristić D, Vukosavljević M, Draganić B, Cerović V, Petrović N, Janićijević-Petrović M.
    Vojnosanit Pregl; 2013 Jul; 70(7):660-3. PubMed ID: 23984614
    [Abstract] [Full Text] [Related]

  • 39. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.
    Retina; 2007 Jul; 27(4):439-44. PubMed ID: 17420695
    [Abstract] [Full Text] [Related]

  • 40. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU.
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.